HLA-C and type 1 diabetes mellitus: A few examples for the treatment of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE) and type I diabetes (T1D), include iron oxide NPs, which have been popularly conjugated to high-avidity MHC peptide ligands, and gold NPs, modified with T-cell epitopes and 2-(1′H-indole-3′-carbonyl)-thiazole-4-carboxylic acid methyl ester [42,43,44].